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Over the last decades, the endocannabinoid system has been implicated in a large vari-
ety of functions, including a crucial modulation of brain-reward circuits and the regulation
of motivational processes. Importantly, behavioral studies have shown that cannabinoid
compounds activate brain reward mechanisms and circuits in a similar manner to other
drugs of abuse, such as nicotine, alcohol, cocaine, and heroin, although the conditions
under which cannabinoids exert their rewarding effects may be more limited. Furthermore,
there is evidence on the involvement of the endocannabinoid system in the regulation of
cue- and drug-induced relapsing phenomena in animal models. The aim of this review
is to briefly present the available data obtained using diverse behavioral experimental
approaches in experimental animals, namely, the intracranial self-stimulation paradigm,
the self-administration procedure, the conditioned place preference procedure, and the
reinstatement of drug-seeking behavior procedure, to provide a comprehensive picture
of the current status of what is known about the endocannabinoid system mechanisms
that underlie modification of brain-reward processes. Emphasis is placed on the effects
of cannabinoid 1 (CB1) receptor agonists, antagonists, and endocannabinoid modulators.
Further, the role of CB1 receptors in reward processes is investigated through presen-
tation of respective genetic ablation studies in mice. The vast majority of studies in the
existing literature suggest that the endocannabinoid system plays a major role in modu-
lating motivation and reward processes. However, much remains to be done before we
fully understand these interactions. Further research in the future will shed more light on
these processes and, thus, could lead to the development of potential pharmacotherapies
designed to treat reward-dysfunction-related disorders.
Keywords: cannabinoids, endocannabinoid system, brain-reward system, intracranial self-stimulation, self-
administration, conditioned place preference, reinstatement of drug-seeking behavior, CB1 receptors
INTRODUCTION
Cannabis is considered as one of the oldest and most widely used
recreational drugs in the world. Its consumption has increased
dramatically in recent decades along with questions of its catego-
rization as an illegal substance (1–4). The attraction of cannabis
and the many issues surrounding its illegality stem from its effects
on sensory processing, euphoric sensations, and its relaxing infer-
ences. These effects are mainly attributed to the key psychoac-
tive ingredient of marijuana,∆9-tetrahydrocannabinol (∆9-THC)
(5–8). The effects of this psychoactive component lead to drug-
seeking behavior and drug abuse in humans (1, 4). Conversely,
investigation of the rewarding effects of ∆9-THC and other syn-
thetic cannabinoids in animal models of drug abuse and depen-
dence has provided us with valuable information on the biphasic
effects of these compounds through contradictory findings (9–
11). The discovery of the endogenous cannabinoid system has
fueled the progressing amount of cannabinoid research in recent
years, with particular emphasis on the effects of endogenous and
synthetic cannabinoid compounds on cannabinoid 1 receptors
(CB1 receptors) found in different areas of the brain. This system
is thought to modulate the motivational processes and reward-
seeking behaviors associated with the use of cannabis. Hence, the
present review summarizes recent animal studies that investigate
the function of the endocannabinoid system and its involvement
in brain-reward systems, with particular emphasis on the role of
CB1 receptors.
ENDOGENOUS CANNABINOID SYSTEM
DEFINITION
The endogenous cannabinoid or endocannabinoid system was
first identified in the early 1990s when researchers were trying
to shed light on the mechanisms of action of ∆9-THC (12–15).
For the past couple of decades, with the contribution of various
research groups, it has been discovered that the endocannabinoid
system is composed of cannabinoid 1 and 2 receptors (CB1, CB2,
respectively, and possibly others), endogenous ligands for these
receptors and enzymes responsible for the synthesis, reuptake and
degradation of these endogenous ligands (14, 16, 17). Genetic,
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pharmacological, and behavioral methods have all been utilized in
order to elucidate the function and mechanisms of this system.
CANNABINOID RECEPTORS
The discovery of ∆9-THC has resulted in a wealth of research
surrounding cannabinoid receptors. Further, the discovery of syn-
thetic cannabinoid agonists with the ability to simulate the effects
of ∆9-THC suggested the existence of specific cannabinoid recep-
tors (18) and increased our understanding of the mechanisms of
action of∆9-THC and the function of cannabinoid receptors. Two
cannabinoid receptors have so far been identified, CB1 (19, 20) and
CB2 receptors (21), both of which are metabotropic receptors cou-
pled to Gi/o proteins. CB1 receptors are observed throughout the
central and peripheral nervous system, but with higher concentra-
tions in the brain and spinal cord (22). This convergence of CB1
receptors in the central nervous system (CNS) is consistent with
the studied behavioral and physiological effects of cannabinoids
(23). High levels of these receptors are found in brain areas such
as the hippocampus, which may explain the memory deficits asso-
ciated with the use of cannabis. Similarly, a high concentration of
these receptors is also observed in brain areas, such as the basal gan-
glia and cerebellum, associated mainly with motor function and
coordination (24, 25). The mesocorticolimbic dopaminergic path-
way of the brain similarly features a high amount of CB1 receptors.
Brain areas that are part of the mesocorticolimbic dopaminergic
pathway include the prefrontal cortex, the hippocampus, the olfac-
tory bulb, and the nucleus accumbens, all of which are implicated
in motivational and reward processes, which have also been found
to be altered by cannabinoid compounds (26, 27). CB1 receptors
are also thought to inhibit release of glutamate, GABA, and other
neurotransmitters, such as dopamine (28). More recent evidence
suggests that CB2 receptors are also implicated in the moderation
of cannabinoids in the CNS (28). Further, a number of behavioral
and pharmacological effects of cannabinoid compounds cannot
be explained by their action specifically on CB1 and CB2 recep-
tors, proposing the existence of additional cannabinoid receptors,
further to be identified and characterized (29, 30).
ENDOCANNABINOID LIGANDS AND THEIR METABOLIZING ENZYMES
The discovery of cannabinoid receptors alludes to the existence of
endogenous ligands that bind and impact the function of these
receptors. The two most widely studied endocannabinoids are N -
arachidonoylethanolamide (AEA), also called anandamide (31)
and 2-arachidonoylglycerol (2-AG) (32, 33), which were first dis-
covered in the early 1990s. Endocannabinoids are synthesized on
demand, mainly postsynaptically and act as retrograde messen-
gers regulating the presynaptic release of neurotransmitters (34).
This occurs in response to physiological and pathological stim-
ulus resulting after an increase of the intracellular concentration
of Ca2+ (35). Different pathways are involved in the synthesis of
AEA and 2-AG. AEA is formed by transacylation of phosphatidyli-
nositol and subsequent degradation by the phospholipid precursor
N -acetyl-phosphatidylethanolamine (NAPE), as well as via a path-
way involving the phospholipase C (PLC)-catalyzed cleavage of
NAPE to generate a lipid, phosphoanandamide, which is sub-
sequently dephosphorylated by phosphatases (36, 37). Although
several pathways have been proposed for 2-AG synthesis, the one
which dominates in the CNS involves the production of 2-AG
via a two-step process: degradation of arachidonate-containing
phospholipids to diacylglycerol (DAG) by PLC followed by DAG
lipase-catalyzed degradation to 2-AG (38). AEA and 2-AG activate
both CB1 and CB2 receptors. These endogenous ligands emu-
late many behavioral and biochemical properties of cannabinoids
(36, 39). In the case of AEA, activation of the transient recep-
tor potential vanilloid type 1 (TRPV1) receptor has also been
noted (40). In recent years, more endocannabinoid ligands have
been discovered such as N -arachidonoyldopamine, virodhamine,
and noladine ether (41, 42). However, the physiological effects of
these endocannabinoids are yet to be revealed. Thus, the focus of
our review will be on effects of AEA and 2-AG, as these are the
first two endocannabinoids discovered and mostly studied. Endo-
cannabinoids are present in the mesolimbocortical dopaminergic
system of the brain (24) suggesting an association with motiva-
tion and reward (31). The control of rewarding processes seems to
be mainly moderated by CB1 receptors. Endocannabinoids can
passively diffuse through lipid membranes, but a highly affin-
ity transporter, which is not yet identified, seems to accelerate
this process. Finally, two types of metabolizing enzymes seem to
play a role in endocannabinoid deactivation, a fatty acid amide
hydrolase (FAAH) is the main hydrolase for AEA, whereas 2-
AG inactivation is mainly degraded by two other enzymes, called
monoacyl-glycerol lipases (MAGLs) (34).
PHARMACOLOGICAL MODULATION OF THE
ENDOCANNABINOID SYSTEM
The discovery of the endocannabinoid system has led to the syn-
thesis of agonists and antagonists that have proven useful in the
investigation of CB1 and CB2 receptors and their functions. Such
pharmacological modulation of the endocannabinoid system has
led to recent advances in behavioral and pharmacological research
(43, 44). There are currently five classes of cannabinoid analogs
that have been classified based on their structure (45–47). These
classes are classical, non-classical, aminoalkylindoles, eicosanoids,
and biarylpyrazoles.
Classical cannabinoids are tricyclic terpenoid derivatives. This
group includes the main psychoactive component of cannabis∆9-
THC, the phytocannabinoid∆8-THC, and other synthetic equiva-
lents. Levonantradol and AMG-3 are two examples of cannabinoid
compounds belonging to this class (43, 44, 48–50).
Non-classical cannabinoids incorporate bicyclic and tricyclic
analogs of ∆9-THC. These include, among others, the potent
non-selective CB1/CB2 receptor agonists CP-55,940, CP-47,497,
and CP-55,244 (43, 51).
The eicosanoid group consists of CB1 and CB2 recep-
tor agonists that have markedly different structures not only
from aminoalkylindoles but also from classical and non-classical
cannabinoids. Notable members of this group are the endo-
cannabinoids AEA and 2-AG (33, 52).
Aminoalkylindoles have a completely different chemical struc-
ture from other classes of cannabinoids. They are less lipophilic
and differ in the way they interact with cannabinoid receptors
(32). The highly studied WIN 55,212-2 is a member of this class
of cannabinoids. It has high stereoselectivity, but low affinity for
the CB2 receptor (48).
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There are many compounds that selectively activate CB1 recep-
tors more effectively than CB2 receptors. Many of these are syn-
thetic analogs of AEA, which include R-(+)-methanandamide,
arachidonyl-2′-chloroethylamide (ACEA), and arachidonylcyclo-
propylamide (ACPA) (48, 53). Although this is not the focus of this
review, compounds with a selective affinity for CB2 receptors have
also been developed and feature cannabinoids such as JWH-133,L-
759633,and L-759656,and the non-classical cannabinoid HU-308.
Other selective CB2 receptor agonists are the aminoalkylindoles
JWH-015 and AM1241 (43, 44, 48).
Many selective compounds have been used extensively in
research as CB1 receptor competitive antagonists. Two of the most
well-known members of this group are SR141716A (rimonabant),
AM-251, as well as AM-281 and LY320135 (47, 54, 55). These
cannabinoids have greater affinity for CB1 receptors than for CB2
receptors and can also inhibit agonist-induced activation of CB1
receptors. In some cases, however, these can act as inverse ago-
nists (47). Recently, compounds have been developed that act as
CB1 receptor antagonists, yet they do not induce signs of inverse
agonism at these receptors. Cannabinoids such as NESS O327, O-
2050, and AM4113 show such effects (47, 56). In addition, the
compounds AM630 and SR144528 are stronger in blocking CB2
than CB1 receptor activation (57, 58). However, both are consid-
ered to be CB2 receptor inverse agonists, due to the fact that, when
administered alone, they can cause inverse cannabimimetic effects
in CB2 receptor-expressing tissues (59).
Other cannabinoids that show an affinity for CB1 and/or
CB2 receptors are the phytocannabinoids cannabinol, cannabid-
iol, and cannabigerol. Cannabinol acts as a CB1 receptor par-
tial agonist, yet there is evidence to suggest that it can also
serve as a CB2 receptor agonist/inverse agonist (60). Cannabid-
iol and cannabigerol have been shown to act as CB1 receptor
antagonists/inverse agonists. Furthermore, cannabidiol has been
found to have considerable potency as a CB2 receptor antag-
onist/inverse agonist (61). Recent research has indicated that
the actions of AEA and 2-AG are halted by cellular uptake
and intracellular enzymatic hydrolysis. This has been highlighted
by the synthesis of several drugs that inhibit these actions
(62–64). The use of these drugs as tools in animal experi-
ments has elucidated the pathophysiological actions of endo-
cannabinoids. Significant members of this group include the
FAAH inhibitors/indirect agonists PMSF, palmitylsulphonyl flu-
oride (AM374), stearylsulphonyl fluoride (AM381), O-1887, OL-
135, URB-532, URB-597, and URB-602 (65–67). In the last few
years, selective pharmacological tools that disrupt the activity
of MAGL in vivo have also become available. MAGL activity is
sensitive to general serine hydrolase inhibitors, such as PMSF.
However, as such compounds also inhibit FAAH, they are not
suitable to distinguish the function of these enzymes. More selec-
tive compounds include URB602, NAM, OMDM169, JZL184, and
KML29 (68).
There is some pharmacological evidence that points toward
the existence of the reuptake transporter of endocannabinoids
through the use of specific reuptake inhibitors. Amongst these
reuptake inhibitors, AM-404 is the most widely investigated. How-
ever, this compound not selective, as it also halts the action of
FAAH and binds to CB1 receptors (67).
GENETIC MODULATION OF THE ENDOCANNABINOID
SYSTEM
Transgenic mice have been used in recent research to understand
the pharmacological and behavioral actions of cannabinoids [for
details on genetic modulation of the endocannabinoid system,
please see Ref. (69–71)]. These mice lack CB1, CB2, or both CB1
and CB2 receptors. They have proven useful tools to elucidate
whether responses to cannabinoid compounds are attributed to
CB1 receptors and/or CB2 receptors as well as the physiological
roles of these receptors (70, 71). FAAH- and MAGL-deficient mice
are also useful in understanding the physiological role of these
endocannabinoid components in various functions and disorders,
including brain reward and drug addiction (68, 72). However, sev-
eral adaptive changes in CB1 receptor function have been reported
in MAGL knockout mice, limiting the use of these mutants in
behavioral studies. Recently, a novel line of transgenic mice that
overexpress MAGL in the forebrain has been generated. Since these
mice do not express adaptive changes in other endocannabinoid
components, this opens the possibility to expand the study of the
physiological role of 2-AG in brain reward processes and drug
addiction (73).
CANNABINOID EFFECTS ON BRAIN REWARD PROCESSES
CANNABINOID EFFECTS ON BRAIN-STIMULATION REWARD
Intracranial self-stimulation (ICSS) is an operant behavioral para-
digm in which animals would work to obtain intracranial stimula-
tion through electrodes implanted into discrete brain areas (often
referred as brain reward areas/circuit) (74, 75). This observation
is based on the original discovery by Olds and Milner (76) that
rats will repeatedly press a lever to stimulate components of their
brain reward circuit. Historically, ICSS has been utilized in rodents
to study how pharmacological or molecular manipulations affect
brain reward function (77). More importantly, manipulations that
increase reward and manipulations that decrease reward produce
opposite outputs in self-stimulation behavior. Accordingly, most
drugs of abuse are able to lower ICSS threshold (i.e., increase the
rewarding efficacy of intracranial stimulation), which support the
notion that they activate the same substrate with electrical stimula-
tion in a synergistic manner (78–80). Thus, ICSS can be considered
as a model to study the reward-facilitating effects of various drugs
of abuse with addictive properties in humans.
Over the last years, a considerable amount of literature has been
published on the effects of cannabinoids in the ICSS paradigm (see
Table 1). Importantly, different effects have been observed after
the administration of∆9-THC or other CB1 receptor agonists and
endocannabinoid modulators. Overall, the corresponding findings
appear to be dispersed and dependent on various methodologi-
cal variables (i.e., strain of the animal, cannabinoid compound,
and dose).
A number of studies have been conducted on the effects of
∆9-THC in the ICSS paradigm. Gardner and colleagues were
among the first who studied the effects of ∆9-THC on ICSS. In
their experiments, 1 and 1.5 mg/kg of ∆9-THC decreased ICSS
thresholds in Lewis rats, but not in Fisher 344 rats, whereas in
Sprague-Dawley rats the effect was only marginal (83, 85). In
contrast, other studies failed to show an enhancement of brain-
stimulation reward with ∆9-THC in the dose range from 0.5
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Table 1 | Cannabinoid effect on intracranial self-stimulation in experimental animals.
Cannabinoid drug Dose Effect Species Reference
∆9-THC, nabilone, canbisol 0.12–10 mg/kg ↑Threshold Long-Evans rats (81)
Levonantradol 0.2, 0.3 mg/kg ↑Threshold Albino CDF rats (82)
∆9-THC 1.5 mg/kg ↓Threshold Lewis rats (83)
∆9-THC 1 and 1.5 mg/kg ↓Threshold Lewis rats (84)
∆9-THC 1 mg/kg – Sprague-Dawley rats (85)
– Fischer 344 rats
↓Threshold Lewis rats
CP 55,940 10, 25, 50 µg/kg – Lewis rats (86)
SR141716A 1, 3, 10 mg/kg ↑Threshold Sprague-Dawley rats (87)
WIN 55,212-2 0.1, 0.3 and 1 mg/kg ↑Threshold Sprague-Dawley rats (88)
WIN 55,212-2 0.1, 0.3, 1, 3 mg/kg ↑Threshold Sprague-Dawley rats (89)
CP 55,940 10, 30, 56, 100 µg/kg
HU-210 10, 30, 100 µg/kg
SR141716A 0.02 mg/kg (Reversing effect on agonists)
AMG-3 1, 2, 4, 8 mg/kg ↑Threshold Sprague-Dawley rats (90)
PMSF 15, 30, 60 mg/kg ↑Threshold Sprague-Dawley rats (91)
OMDM-2 3, 10, 30 mg/kg
URB-597 0.3, 1, 3 mg/kg
SR141716A 0.02 mg/kg (Reversing effect on modulators)
SR141716A 0.1–10 mg/kg ↑Threshold CB1-knock out mice (92)
AM251 0.1–10 mg/kg – CB1-knock out mice (92)
∆9-THC 1–2 mg/kg ↑Threshold (reversing effect on ∆9-THC) Sprague-Dawley rats (93)
SR141716A 0.02 mg/kg (93)
AM-251 3 mg/kg ↓ Opportunity cost Long-Evans rats (94)
∆9-THC 0.32–1 mg/kg – Sprague-Dawley rats (95)
SR 3.2 and 10 mg/kg ↑Threshold
CP 1 mg/kg – (But reversed THC effects)
0.01–0.032 mg/kg –
0.1 and 0.32 mg/kg ↑Threshold
∆9-THC 0.1 mg/kg ↓Threshold Sprague-Dawley rats (96)
1 mg/kg ↑Threshold
URB-597 1 mg/kg – Sprague-Dawley rats (97)
3.2 and 10 mg ↑Threshold
– No effect on threshold, ↑ increase, ↓ decrease, – no effect.
to 10 mg/kg in Sprague-Dawley rats under baseline conditions
(93, 95, 96) or in animals pre-exposed to stress (98). Similar
results have been reported in Long-Evans rats with p.o adminis-
tration of 10/mg/kg∆9-THC and various doses of three synthetic
analogs structurally related to ∆9-THC, namely levonantradol,
nabilone, and canbisol (81, 82). Interestingly, however, in a recent
study from our research group, we showed that ∆9-THC can
induce both rewarding and anhedonic effects in the ICSS para-
digm in Sprague-Dawley rats, depending on the dose used (96).
Thus, a low dose of 0.1 mg/kg, decreased ICSS thresholds and
caused clear parallel leftward shifts in the rate-frequency func-
tion, whereas a higher dose of 1 mg/kg increased ICSS thresholds,
producing rightward shifts. These effects were long-lasting, since
they remained for 2 h post-injection and the reward-facilitating
effect that we observed with 0.1 mg/kg of ∆9-THC was more pro-
nounced after 1 h. Both the rewarding and the anhedonic effects
of ∆9-THC observed in our studies are specifically mediated by
cannabinoid CB1 receptors, since they have been reversed by a
low dose of SR141716A. Comparing findings from the above
studies, it can, thus, be suggested that Lewis rats may have a
differential sensitivity to ∆9-THC, compared to Sprague-Dawley
and Fisher 344 rats and that the dose–response function of
∆9-THC on brain-stimulation reward is not linear, but rather
biphasic.
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Only a few studies have examined the effects of various syn-
thetic cannabinoid agonists on brain-stimulation reward. Arnold
and colleagues have reported that the potent synthetic CB1 recep-
tor agonist CP55,940 did not affect the reinforcing efficacy of
medial forebrain bundle (MFB) stimulation (86). In the same
way, other studies have shown that the synthetic CB1 receptor
agonists WIN55,212-2, CP55,940, HU-210, and AMG-3 either do
not affect or increase ICSS threshold, depending on the dose used
(88–90, 95). Similarly, in a series of studies from our laboratory we
have shown that the indirect cannabinoid agonists (endocannabi-
noid modulators) PMSF, AM-404, OMDM-2, and URB-597 in
low doses do not affect ICSS thresholds, while in high, and possibly
non-selective doses, decrease the reinforcing efficacy of brain stim-
ulation (91, 99). Similar results have been reported very recently
with the FAAH inhibitor URB-597 (97).
Several studies have examined the effects of CB1 receptor
antagonists on ICSS. Low doses of the CB1 receptor antagonists
SR141716A and AM-251 did not affect ICSS thresholds (89–92,
95), while higher doses of SR141716A have been reported to
increase ICSS thresholds (86, 87, 92) However, in such high doses
it is possible that SR141716A acts as a partial or inverse agonist
at cannabinoid receptors, as it has been observed in other studies
(100, 101). Indeed, this could be a plausible explanation for its
anhedonic effects observed with high doses on brain-stimulation
reward. Shizgal’s group (94) utilizing a novel method for measur-
ing reward have shown that AM-251 decreased performance for
MFB self-stimulation. Indeed, AM-251 produced leftward shifts of
the function that relates operant performance to the opportunity
cost of the reward, but did not affect the function that relates oper-
ant performance to the stimulation strength. The authors suggest
that this shift may be related to a decrease in the reward signal gain
or an increase in the subjective reward cost.
In summary, although most drugs abused by humans are able
to increase the rewarding efficacy of brain stimulation over a wide
range of doses, results with∆9-THC and other synthetic cannabi-
noid agonists have not always been consistent. In the studies by
Gardner’s group, the most robust reward-facilitating effect of ∆9-
THC in the ICSS paradigm was found in rats of the Lewis strain.
Thus, it is possible to hypothesize that the reward-facilitating effect
of ∆9-THC may preferentially be obtained in certain strains of
rat, suggesting an important genetic component in this action.
One major finding was that ∆9-THC induces biphasic effects, i.e.,
is able to induce both rewarding and anhedonic effects, in the
ICSS paradigm in Sprague-Dawley rats, depending on the dose
used. On the other hand, studies using the ICSS paradigm failed
to show any reward-facilitating effects for direct and indirect (i.e.,
endocannabinoid modulators) synthetic cannabinoid agonists, or
to the contrary, they present data for anhedonic actions of these
compounds. Thus, it is possible that cannabinoids have negative
or dysphoric effects in animals that mask their reward-facilitating
effects in the ICSS paradigm and that these effects are suppressed
under a limited dose range.
CANNABINOIDS EFFECTS ON CONDITIONED PLACE PREFERENCE
Conditioned place preference (CPP) is a non-operant procedure
for assessing the reinforcing properties of drugs using a Pavlov-
ian conditioning. The reinforcing properties of abused drugs are
easily associated with environmental stimuli, such as an environ-
ment or context in which the drugs are administered. Through
multiple pairings, these environmental (contextual) cues acquire
conditioned reinforcing properties. The CPP paradigm is based on
the assumption that animals learn to approach stimuli paired with
rewards and to avoid stimuli paired with aversive agents. Thus,
it can be used to evaluate whether the repeated pairing of one
specific environment with a drug produces a preference for that
environment (102). Indeed, in this procedure, the animal devel-
ops an association between the subjective state produced by the
drug (e.g., a heightened feeling of euphoria comparable to plea-
sure in humans) and the environmental cues present during the
drug state. Most drugs abused by humans produce place prefer-
ence in experimental animals (103). Although CPP provides a less
direct evaluation of the rewarding effects of drugs, it presents sev-
eral advantages: (1) it can be sensitive even to low doses of the drug
studied, (2) it can be also used to assess the aversive or dysphoric
properties of a drug (in this case, the animal will avoid staying in a
compartment previously associated with a drug), (3) the animals
are tested in a drug-free state, (4) it can be used to study non-drug
stimuli, such as food, sucrose, or sex.
Studies using the CPP paradigm have shown that ∆9-THC
and other synthetic cannabinoid agonists can induce both appet-
itive and aversive effects under various experimental conditions
(see Table 2). Notably, in the studies reporting place preference
of cannabinoids, these effects are usually dependent upon the
particular dose used and the preference is connected to a single
dose. Furthermore, other factors, such as the administration of
a priming injection and the timing between injections have been
suggested to be important in determining whether cannabinoids
produce preference or aversion.
In the first study, ∆9-THC-produced CPP was published in
1995 by the Gardner research group (104). In their experiments,
2–4 mg/kg ∆9-THC produced CPP in Long-Evans rats, when the
CPP pairing interval was 24 h, while the dose of 1 mg/kg of ∆9-
THC did not produce any preference. However, when the schedule
of daily injections was changed, allowing a longer wash-out inter-
val between injections (48 h), ∆9-THC produced a clear place
aversion in the dose range of 2–4 mg/kg, but place preference
in the dose of 1 mg/kg. In other words, ∆9-THC-induced CPP
was dependent upon the dose and the injection schedule. Similar
results have been reported by Braida and colleagues (117) and
Le Foll and colleagues (122). In the first study, ∆9-THC pro-
duced CPP in Wistar rats in a dose range between 0.075 and
0.75 mg/kg, whereas higher doses produced aversive effects. In
the latter study, a low 0.1 mg/kg dose of ∆9-THC produced CPP,
while doses lower or higher than this did not produce any prefer-
ence. Two other studies in male Lister-Hooded rats not only failed
to find any rewarding effects of ∆9-THC (1.5 and 2 mg/kg) in
the CPP paradigm, but reported aversive effects (111, 116). Two
more recent studies did not find any rewarding or aversive effects
of ∆9-THC in the CPP paradigm in Sprague-Dawley rats and
in the dose range of 0.1–3 mg/kg (136, 141). A few studies have
examined whether adolescent rats respond differently (are more
vulnerable) to ∆9-THC than adult rats. According to a study by
the McGregor group (125), ∆9-THC (5 mg/kg) produced CPA
in adult rats, whereas in adolescent rats there was only a trend
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Table 2 | Cannabinoid effects on conditioned place preference in experimental animals.
Cannabinoid drug Dose Effect Species Reference
∆9-THC 1 mg/kg – Long-Evans rats (104)
2 and 4 mg/kg CPP
2 and 4 mg/kg (wash-out period) CPA
1 mg/kg CPP
∆9-THC 1 mg/ml CPA Lewis and Sprague-Dawley
rats
(105)
CP 55,940 100µg/kg CPA Wistar rats (106)
∆9-THC 1.5 mg/kg – Sprague-Dawley rats (107)
15 mg/kg CPA
WIN 55,212-2 0.3–1 mg/kg CPA Wistar rats (108)
SR141716A Up to 10 mg/kg –
(reversing effect on WIN 55,212-2)
∆9-THC 20 mg/kg CPA CD1 mice (109)
∆9-THC 1 and 1.5 mg/kg CPA Wistar rats (110)
Anandamide (AEA) up to 16 mg/kg -
HU-210 20, 60, 100 µg/kg CPA Lister Hooded rats (111)
∆9-THC 1.5 mg/kg CPA
∆9-THC 5 mg/kg CPA CD1 mice (112)
1 mg/kg –
5 mg/kg (not standard
protocol-pre-treatment)
–
1 mg/kg CPP
CP 55,940 20µg/kg CPP Wistar rats (113, 114)
SR141716A 0.5 mg/kg –
(Reversing effect on CP 55,940)
∆9-THC 5 mg/kg - dynorphin deficient mice (115)
∆9-THC 2 mg/kg CPA Lister Hooded rats (116)
WIN 55,212-2 1 and 3 mg/kg –
∆9-THC 0.075–0.75 mg/kg CPP Wistar rats (117)
SR141716A 0.25–1 mg/kg (Reversing effect on ∆9-THC)
WIN 55,212-2 mg/kg (+pre-treatment) CPP CD1 mice (118)
1 mg/kg (+pre-treatment) –
∆9-THC 1 mg/kg CPP A2AKO and wild-type mice (119)
5 mg/kg CPA
URB-597 0.03–0.3 mg/kg – Wistar, Sprague-Dawley rats (120)
AM-404 1.25–10 mg/kg CPP Rats (anxiety models) (121)
–
∆9-THC 0.1 mg/kg CPP Sprague-Dawley rats (122)
∆9-THC 1 mg/kg – C57B1/6Lx129Sv mice (93)
Anandamide 0.03–3 mg/kg, iv – Sprague-Dawley rats (123)
WIN 55,212-2 0.3 and 3 mg/kg, iv (+URB-597
0.3 mg/kg, ip)
CPA
AM-251 50, 150, and 300 mg/kg, iv CPA
3 mg/kg, ip –
(Reversing effect on anandamide
and WIN 55,212-2
(Continued)
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Table 2 | Continued
Cannabinoid drug Dose Effect Species Reference
∆9-THC 1 mg/kg – ICR mice (124)
10 mg/kg CPA
∆9-THC 5 mg/kg – Adolescent Wistar rats (125)
5 mg/kg CPA Adult Wistar rats
WIN 0.25, 1.25, 2.5 mg/kg CPA Adult Wistar rat (126)
0.25 mg/kg CPP Adult SHR rats
2.5 mg/kg CPP Adolescent SHR rats
AM-251 0.25 and 0.5 mg/kg – Wistar rats (127)
SR 141716A 0.5, 1 and 2 mg/kg – Wistar rats (128)
WIN 55,212-2 0.5 mg/kg CPP OF1 male mice (129)
0.1 mg/kg –
Intra-accumbal SR141716 0.5µg/µl – Wistar rats (130)
1.5µg/µl CPP
HU-210 100µg CPP Sprague Dawley rats (131)
∆9-THC 10 mg/kg – Albino Wistar rats (132)
SR 141716A 0.3 and 3 mg/kg – Sprague Dawley rats (133)
HU-210 100µg CPP Sprague Dawley rats (134)
Intra-CeA ACPA 5 ng CPP Wistar rats (135)
Intra-CeA AM-251 120 ng CPA
AM-404 1.25 mg/kg – Sprague Dawley rats (136)
10 mg/kg CPP
∆9-THC 0.1–3 mg/kg –
Intra-VTA ACPA 0.5 and 1 ng CPA Wistar rats (137)
Intra-Bla ACPA 1 and 2 ng CPP
Intra-VH ACPA 3 ng CPA
6 ng CPP
Intra-accumbal WIN 55,212-2 1, 2, 4 mmol/0.5µl CPP Wistar rats (138)
Intra-accumbal AM-251 90µmol/0.5µl CPA
Intra-VTA WIN 55,212-2 4 mmol/0.3µl CPP Wistar rats (139)
Intra-VTA AM-251 90 mmol/0.3µl Tendency (not significant effect)
toward CPA
JWH-018 0.1 and 1 mg/kg (in drug naïve mice) CPA NIH Swiss mice (140)
0.1 mg/kg (in mice pretreated with
∆9-THC)
CPP
WIN 55,212-2 1 mg/kg – Sprague Dawley rats (141)
∆9-THC 0.5 mg/kg –
(Tendency for CPA)
CPP conditioned place preference, CPA conditioned place aversion (avoidance), – no effect.
toward aversion, which was not significant. Interestingly, the aver-
sive effect reported in adult rats was long-lasting, since the animals
still avoided ∆9-THC-paired environment 16 days following the
last drug exposure. Surprisingly, in a more recent study in ado-
lescent Wistar rats, although ∆9-THC (10 mg/kg) did not induce
CPP when administered alone, it tended to produce a preference
when administered in combination with cannabidiol (132).
Studies in mice have also shown controversial results. Valjent
and Maldonado reported ∆9-THC-induced CPP bypassing the
dysphoric/aversive effects of ∆9-THC that has been reported in
naïve animals with a priming injection 24 h before the first con-
ditioning session (112). However, Vlachou and colleagues did not
observe CPP with the 1 mg dose of∆9-THC using the same exper-
imental manipulation (93). These differences can be explained in
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part by the different strain of animals used, the number of pair-
ings or the periods of conditioning, and administration of the
drugs. Although the Maldonado group replicated their findings in
a subsequent study (119), it is worth noting that they also report
conditioned place aversion (CPA) with the dose of 5 mg/kg of
∆9-THC. Finally, a number of studies have found that ∆9-THC
produces CPA and not CPP in rats or mice (105,107,109,110,124).
Bidirectional and/or conflicting effects have been also reported
in the literature for synthetic cannabinoid agonists. In a very
recent study, the synthetic cannabinoid agonist JWH-018 pro-
duced CPA in naïve mice, but CPP in mice pre-treated with ∆9-
THC (140). Thus, we could speculate that ∆9-THC pre-exposure
may reveal the appetitive effects of other cannabinoid agonists.
Braida and colleagues using the potent synthetic CB1 receptor
agonist CP55,940 in Wistar rats reported CPP only at the dose of
20µg/kg, but not in lower or higher doses (113). Another study
using CP55,940 reported CPA in the dose of 10µg/kg, as well as
in a higher dose of 100µg/kg (106). In the same study, the dose
of 100µg/kg of CP55,940 was also aversive in the conditioned
taste aversion paradigm. The literature on the reinforcing effects of
WIN55,212-2 and HU-210 in the CPP paradigm is also controver-
sial. According to Castané and colleagues, WIN55,212-2 produced
CPP in mice pre-exposed to a priming injection of the drug (118).
Similar results have also been reported with HU-210 (100µg/kg)
in Sprague-Dawley rats pre-exposed to a priming phase consisting
of four daily home injections of the drug (131, 134). Notably, CPP
with WIN55,212-2 has also been reported in OF1 mice without
utilizing a pre-exposure protocol (129). However, two other stud-
ies reported CPA after systemic administration of WIN55,212-2
(108) and HU-210 (111). Adding to this complexity are stud-
ies that failed to reveal either a preference or an aversive effect
with WIN55,212-2 in a dose range between 0.1 and 3 mg/kg (116,
142). Contrasting effects of WIN55,212-2 in Wistar and sponta-
neously hypertensive rats, a validated animal model of attention
deficit/hyperactivity disorder, have been reported in the literature
(126). Thus, WIN55,212-2 produced CPA only in adult, but not
adolescent Wistar rats. In contrast, WIN55,212-2 produced CPP
in both adolescent and adult spontaneously hypertensive rats.
A limited number of studies have also examined the effect
of intracranial injections of CB1 receptor agonists and antago-
nists in the CPP paradigm. Data from two recent studies have
shown that intra-accumbal (138) and intra-VTA (139) injection
of WIN55,212-2 produces CPP. In contrast, intra-accumbal (138)
or intra-central amygdala (135) injection of the CB1 receptor
antagonist AM-251 produces CPA, while intra-VTA injection of
AM-251 produces a tendency toward CPA (139). Similarly, intra-
central amygdala (135) and intra-basolateral amygdala injection
of the cannabinoid agonist ACPA produces CPP, whereas intra-
VTA injection of ACPA produces CPA (137). Interestingly,biphasic
effects of intra-ventral hippocampus injection of ACPA have also
been reported in the literature in the CPP test, with lower doses
producing CPP, while higher doses CPA (137).
Although most of the studies have used CB1 receptor antag-
onists to test for CB1-receptor selectivity of cannabinoid com-
pounds on brain reward, there are a few studies that have tested
the effects of CB1 receptor antagonists on reward per se. Cheer
and colleagues found that the CB1 receptor antagonist/inverse
agonist SR141716A produced a clear CPP (111), indicating the
possibility that an endogenous cannabinoid tone might be present
in the brain, as a physiological system to suppress reward or
induce aversion. Importantly, in a major study, intra-accumbens
injection of SR141716A also produces CPP, although in vivo
silencing of accumbal CB1 receptors induced CPA to cocaine
(130). Based on these results, the authors suggest that SR141716A
acts as an inverse agonist on the CPP test. However, in other
studies SR141716A or AM-251 failed to produce either CPP or
CPA (108, 113, 127, 128, 133).
A limited number of studies have examined the effects of
endogenous cannabinoids or compounds increasing their levels
in the brain on CPP. The first report that the administration of
the endogenous cannabinoid anandamide did not produce any
significant effects in place conditioning was published by Mallet
and Beninger (110). As anandamide is quickly degraded, its phys-
iological roles can be best studied by blocking the mechanisms of
its degradation and, thus, prolonging its actions. As previously
described, anandamide degradation is mainly mediated by the
enzyme FAAH. Accordingly, inhibition of FAAH by drugs, such
as URB-597, can be used as a pharmacological tool to study the
role of anandamide in brain reward. In a study investigating the
antidepressant properties of URB-597, Gobbi and colleagues (120)
did not find any rewarding effects in the CPP paradigm. In another
major study (123), intravenous administration of anandamide did
not produce CPP or CPA. However, when rats were pretreated with
the FAAH inhibitor, URB597 anandamide produced dose-related
CPA (123).
As mentioned previously, termination of endocannabinoid sig-
naling is also mediated by cellular uptake. Inhibition of endo-
cannabinoid transport by drugs, such as AM-404, is an additional
pharmacological tool to study the role of endocannabinoids on
brain reward. CPP by AM-404 was first demonstrated experi-
mentally by Bortolato and colleagues (121) in rats housed under
enriched conditions, but not in rats kept in standard cages. How-
ever, it is worth noting that AM-404 induced CPP at a dose that did
not increase tissue levels of anandamide or 2-AG in the brain areas
investigated (121). Thus, the involvement of the endocannabinoid
system in AM-404-induced CPP remains questionable. In a more
recent study, Scherma and colleagues examined different doses
(1.25–10 mg/kg) of AM-404 in the CPP test and found that only
the high dose of 10 mg/kg was able to produce a clear CPP in
Sprague-Dawley rats (136).
In summary, while almost all drugs abused by humans are
able to produce a clear and reliable place preference (i.e., increase
the time spent in the drug paired compartment) over a range
of doses, results with ∆9-THC and other cannabinoids have not
always been consistent. The studies reporting a CPP associated
with administration of a cannabinoid have either used a particu-
lar experimental methodology or the preference occurred at only
a single dose. In addition, although endocannabinoids are able to
regulate reward-related processes, they do not produce CPP and do
not seem to have reinforcing properties that have been associated
with ∆9-THC and other cannabinoid receptor agonists. It is pos-
sible, therefore, that the rewarding properties of cannabinoids in
the CPP procedure may be masked by aversive or dysphoric effects,
under particular circumstances. Thus, we highlight the difficulty
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of drawing general conclusions on whether ∆9-THC and other
cannabinoids have reinforcing properties in the CPP paradigm.
CANNABINOID EFFECTS ON SELF-ADMINISTRATION
STUDIES
Human subjects and laboratory animals will self-administer addic-
tive drugs by a variety of routes, including oral, intragastric,
intraperitoneal, and intracranial routes. Intravenous drug self-
administration has been one of the most direct approaches to
study the rewarding properties of drugs of abuse in experimental
animals, such as rodents or primates. In this behavioral paradigm,
based on operant conditioning, animals learn to make an oper-
ant response, such as pressing a lever in an operant chamber or
inserting their nose into a hole, to self-administer a reinforcer
(e.g., a drug of abuse) after the completion of the reinforce-
ment schedule requirement. A reinforcer is an event that follows
a response and increases the probability of a response to reoccur
(143–147). Reinforcing effects of a drug assessed by intravenous
self-administration procedures in experimental animals are con-
sidered as one of the most reliable predictors of abuse potential in
human subjects. The main schedules of reinforcement used in the
self-administration procedure to resemble the human condition
are the fixed-ratio, the progressive-ratio, and the discrete-trials
schedules of reinforcement.
Briefly, under the fixed-ratio schedule, the reinforcer is deliv-
ered every time a predetermined number of responses is com-
pleted, and the delivery of a reinforcer is usually followed by
a timeout period in self-administration studies to prevent the
subjects from overdosing (e.g., FR1 or continuous reinforcement
schedule, FR2, FR4, FR5, etc.). Data obtained from a fixed-ratio
schedule provide a measure of drug intake and reinforcement effi-
cacy. Further, under the progressive-ratio schedule, the response
requirements are progressively increased after the delivery of each
reinforcer, according to a predetermined progression. For exam-
ple, the number of responses required to earn a nicotine infusion
or food pellet on the progressive-ratio can be determined by the
exponential progression [5e(0.25× (infusion number+ 3))− 5] with the
first two values replaced by 5 and 10, so that the response require-
ments for successive reinforcers are 5, 10, 17, 24, 32, 42, 56, 73, 95,
124, 161, 208, etc. Breakpoints in this schedule are typically defined
as the highest response rate achieved to obtain a single reinforcer
before an animal fails to complete the next ratio requirement
within a predetermined time period (e.g., 60 min). Data obtained
from a progressive-ratio schedule provide a measure of the moti-
vation (i.e., incentive value) to obtain a reinforcer. Finally, in the
discrete-trial schedule of reinforcement procedure, only a single
injection of the drug is delivered during individual trials. The
intertrial interval (ITI) can be adjusted to manipulate the influ-
ence of one injection on subsequent trials. When short ITIs are
used, animals continuously self-administer a drug for long periods
of time (hours or even days). When long ITIs are used, a regular
circadian pattern of self-administration occurs (i.e., periods of
abstinence during the light phase of the cycle alternate with peri-
ods of self-administration during the dark phase). Data obtained
from a discrete-trials schedule provide a measure of the motiva-
tion to initiate drug-taking behavior. Thus, all three schedules can
reliably predict abuse potential in human subjects (147).
Most drugs abused by humans, including psychostimulants,
opiates, ethanol, and nicotine, support reliable and persistent
self-administration behavior in drug-naïve experimental animals
(148). However, for many years, it has been rather difficult to
show self-administration of cannabis,∆9-THC or other cannabi-
noid compounds in experimental animals (149–155), with the
first studies showing either no effect of ∆9-THC (156, 157),
self-administration of ∆9-THC only in food- or water-deprived
animals (117, 158–160), or in animals that were previously pre-
exposed to or trained to self-administer other drugs of abuse, such
as phencyclidine, cocaine, amphetamine, ethanol, or pentobarbi-
tal (150, 155, 161–163), with not a robust effect (i.e., relatively low
rates of responding). Interestingly, in the past few years, differ-
ent research groups have successfully varied the parameters of
self-administration procedure in order to demonstrate reliable
and persistent self-administration of ∆9-THC or other synthetic
cannabinoids in rodents or primates (see Table 3).
The first self-administration of cannabis, with a low success
rate, was reported by Deneau and Kaymakcalan (156) and Kay-
makcalan (157), who demonstrated acquisition of ∆9-THC self-
administration behavior in two monkeys out of six studied, but
only after withdrawal from forced automatic i.v. injections of ∆9-
THC, when signs of physical dependence on ∆9-THC occurred.
Naïve monkeys did not self-administer ∆9-THC, while one mon-
key exhibited ∆9-THC self-administration behavior following
cocaine self-administration. Furthermore, in a study by Pick-
ens and colleagues (161) where animals had been pre-exposed
to phencyclidine before ∆9-THC self-administration, rates of
responding were relative low and there was no clear evidence
that responding for ∆9-THC could persist above vehicle con-
trol levels over repeated daily sessions. The functional state as
well as the motivational state in naïve animals compared with
animals that self-administer other drugs of abuse could be dif-
ferent, and therefore, their corresponding response could also
vary accordingly (154, 181). Similarly to the above study, food
deprivation was also used to initiate and subsequently main-
tain ∆9-THC self-administration. Takahashi and Singer (158,
159) reported ∆9-THC self-administration above placebo lev-
els in diet-restricted rats maintained at 80% of normal body
weight, under conditions where a food pellet was automatically
delivered every minute. Interestingly, self-administration imme-
diately decreased to placebo levels when food restriction was
discontinued. This manipulation may also alter the motivational
state of the animal, which per se is an inherent limitation, as
it has been repeatedly shown that food restriction (or depri-
vation) can facilitate the initiation and maintenance of drug
self-administration (160, 182–185).
Interestingly, initiation and maintenance of high rates of intra-
venous self-administration of low doses of ∆9-THC in drug-naïve
squirrel monkeys was only accomplished in the past few years (166,
180, 186). In the first of these studies, low doses of ∆9-THC ini-
tiated and sustained high rates of intravenous self-administration
in drug-naïve squirrel monkeys. Three drug naïve squirrel mon-
keys were used and low doses of ∆9-THC (1–8µg/kg/injection)
that, according to the authors, were several times lower than
doses generally used in previous attempts to demonstrate ∆9-
THC self-administration in monkeys and comparable to those
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Table 3 | Cannabinoid effects on self-administration in experimental animals.
Cannabinoid drug Dose Effect Species Reference
WIN 55,212-2 0.05–0.1 mg/kg ↑ SA CD1 mice (164)
0.5 mg/kg ↓ SA
∆9-THC 2 and 4 mg/kg/injection ↑ SA Squirrel monkeys (162)
WIN 55,212-2 6.25–50µg/kg/injection ↑ SA Long-Evans rats (165)
CP 55,940 0.1–1.6 mg/2µl/infusion SA Wistar rats (113, 114)
∆9-THC 2, 4, 8 mg/kg/injection ↑ SA Squirrel monkeys (166)
∆9-THC 2–8µg/kg/injection ↑ SA Squirrel monkeys (167)
WIN 55,212-2 0.6, 1.2 and 1.8 mg/kg ↓ SA Wistar rats (168)
Anandamide (AEA) 40 mg/kg/injection ↑ SA Squirrel monkeys (169)
Methanandamide 10, 20, 40µg/kg/injection ↑ SA (169)
∆9-THC 100 ml injection of 66 or 200 pmol SA Sprague-Dawley rats (170)
WIN 55,212-2 6.25 and 12.5µg/kg/infusion SA CD1 mice (171)
WIN 55,212-2 12.5µg/kg/infusion SA Sprague-Dawley rats (172)
WIN 55,212-2 12.5µg/kg/infusion ↑ SA Lister Hooded and Long Evans rats (173)
WIN 55,212-2 12.5µg/kg/infusion SA Lister Hooded rats (174)
2-Arachidonoylglycerol (2-AG) 0.1–100µg/kg ↑ SA Squirrel monkeys (175)
∆9-THC 0.0032–0.032 mg/kg/infusion SA Rhesus monkeys (176)
∆9-THC 4µg/kg/injection ↑ SA Squirrel monkeys (177)
WIN 55,212-2 12.5µg/kg/infusion ↑ SA Sprague-Dawley rats (177)
WIN 55,212-2 12.5µg/kg/infusion ↑ SA C57BL/6J mice (178)
WIN55,212-2 0.01 mg/kg/infusion ↑ SA Long-Evans rats (179)
∆9-THC 0.003–0.1 mg/kg/infusion SA Long-Evans rats (179)
∆9-THC 4µg/kg/injection ↑ SA Squirrel monkeys (180)
↑ SA: increase, ↓ SA: decrease in self-administration (SA), SA: self-administration in not higher than vehicle/saline levels.
delivered by an average marijuana cigarette. Furthermore, ∆9-
THC was dissolved in a Tween-80 vehicle resulting in a clear
solution that was rapidly delivered (0.2 ml injection delivered
in 200 ms) in the drug-naïve animals. The self-administration
behavior was rapidly extinguished either by substituting vehicle
injections for ∆9-THC injections or by administering the CB1
receptor antagonist SR141716A before the session, demonstrat-
ing that this effect was mediated by direct stimulation of the
CB1 receptors. Most recently, in a study by a different research
group (176), rhesus monkeys could self-administer∆9-THC alone
(0.0032–0.032 mg/kg/infusion), although ∆9-THC alone did not
maintain responding above that obtained with saline.
Importantly, Braida and colleagues also showed intracere-
broventricular self-administration of ∆9-THC in rats under
water-deprived conditions (117), while in a latter study Zangen
and colleagues (170) identified the posterior ventral tegmental area
and the shell of the nucleus accumbens, but not the anterior ventral
tegmental area, the region dorsal to this, or the core of the nucleus
accumbens, as possible brain sites for the rewarding effects of the
reported intracerebral self-administration of ∆9-THC (170).
Synthetic cannabinoid analogs have also been used in the self-
administration procedure. The most commonly used synthetic
cannabinoid analog is the potent non-selective CB1/CB2 recep-
tor agonist WIN55,212-2. Fattore and colleagues (165) showed
that rats could self-administer intravenously several doses of
WIN55,212-2 under food restriction. This effect was blocked by
the CB1 receptor antagonist SR141716A, indicating that the self-
administration of WIN55,212-2 was mediated by activation of the
CB1 receptors. This finding was replicated in more recent studies
by the same group using the same experimental design (173, 174).
Further, Lecca and colleagues (172) reported self-administration
of WIN55,212-2 in rats following a different experimental protocol
from that of the above mentioned studies. In their study, rats were
not food-restricted, but they were maintained on a daily ratio of
20 g of food, made available at the end of each self-administration
session.
In a most recent study (179), male Long-Evans rats were trained
to self-administer WIN55,212-2 (0.01 mg/kg/infusion) on a fixed
ratio 3 schedule. Dose–effect curves for WIN55,212-2 were deter-
mined, followed by vehicle substitution and a dose–effect curve
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with ∆9-THC. WIN55,212-2 self-administration was acquired;
however, substitution with∆9-THC did not maintain responding
above vehicle levels. WIN55,212-2’s reinforcing effects were CB1
receptor-mediated, as they were dose-dependently attenuated by
SR141716A. As authors indicated, the lack of substitution with
∆9-THC seen in this study is problematic and may suggest that
WIN55,212-2 self-administration may be of limited usefulness as
a screening tool for detection of the reinforcing effects of potential
cannabinoid medications (179).
Importantly, Martellotta and colleagues showed intravenous
self-administration of WIN55,212-2 in mice in a dose-dependent
manner (164). This effect was also blocked by pre-treatment
with the CB1 receptor antagonist SR141716A, indicating the
direct involvement of the CB1 receptors. Self-administration of
WIN55,212-2 in mice under a fixed- and a progressive-ratio sched-
ule of reinforcement was also shown recently (178), an effect
that was blocked by systemic administration of the hypocretin
receptor-1 (Hcrtr-1) antagonist SB334867. This role of Hcrtr-1 in
the reinforcing and motivational properties of WIN55,212-2 was
confirmed in Hcrtr-1 knockout mice (178).
The same experimental protocol as Martellota and colleagues
(164) was also used by another research group (187) to study the
reinforcing effects of WIN55,212-2 in CB1 knockout mice. The
genetically modified mice did not self-administer WIN55,212-2.
In another study, drug-naïve mice self-administered the synthetic
CB1 receptor agonist WIN55,212-2 and the ∆9-THC derivative
HU-210 (188). However, it should be emphasized that these stud-
ies have an important inherent limitation as 1-day experimental
tests were used and the animals were severely restrained. Thus,
validity of these data is questionable and difficult to correlate with
drug addiction in humans, which is a chronic state or even com-
pare with chronic self-administration procedures in animals under
baseline conditions (i.e., no restraint). Furthermore, since the ani-
mals were severely restrained, the reported self-administration
may be affected by analgesic or anxiolytic effects resulting in a
reduction of pain or stress produced by the restrain.
Interestingly, both AEA (as well as its metabolically stable syn-
thetic analog methanandamide) (169) and 2-AG (175) are intra-
venously self-administered by squirrel monkeys, although four out
of six squirrel monkeys used in the first study (169) had a his-
tory of ∆9-THC or methohexital self-administration. Similarly,
in the more recent study indicating 2-AG self-administration,
the researchers used monkeys with either a history of AEA self-
administration or a history of nicotine self-administration (175).
Interestingly, however, the reinforcing effects of AEA and 2-AG
appear to be mediated by cannabinoid CB1 receptors, since daily
pre-treatment with SR141716A resulted in complete blockade of
AEA or 2-AG self-administration behavior. It is also notewor-
thy that in both studies, the authors report rates of responding
comparable with those maintained under the same conditions by
cocaine or∆9-THC. More importantly, there is also evidence that
treatment with the FAAH inhibitor URB597 shifts the AEA self-
administration dose–response curve to the left, indicating that
AEA has rewarding effects even in lower doses (189).
Further, only a few studies have focused on the intracranial
self-administration of ∆9-THC or other cannabinoid analogs by
experimental animals. Intracerebral administration of the potent
non-selective CB1/CB2 receptor agonist CP-55,940 was shown in
rats in a free-choice procedure (114). This effect was antagonized
by the CB1 receptor antagonist SR141716A, indicating that it was
specifically mediated by CB1 receptors. However, one limitation
of this study is that the animals were water-deprived and water
was concurrently delivered with each infusion. This may have
altered the motivational state of the animals, provoking the self-
administration response. In a previous study, CP-55,940 was not
self-administered by rhesus monkeys (155).
In summary, most attempts to obtain a robust self-
administration of∆9-THC or other synthetic cannabinoids,under
regular experimental conditions (i.e., drug-naïve unrestrained ani-
mals, and not food deprived), have been unsuccessful or partly
successful. Only a limited number of studies report a robust pro-
cedure for cannabinoid self-administration either in a limited
number of squirrel monkeys or intracerebrally in rodents. This
is in accordance with other behavioral studies on rewarding and
reinforcing effects of cannabinoids (i.e., ICSS, CPP) and illustrates
the differential status of cannabinoids as atypical drugs of abuse.
CANNABINOID EFFECTS ON REINSTATEMENT PROCEDURES
A procedure used to study cue-, context-, drug-, or stress-induced
reinstatement of drug seeking is hypothesized to be a putative
model of relapse to drug seeking in humans. Animals learn to
self-administer a drug for a period of time, in the same man-
ner as during the self-administration procedure. Drug-reinforced
lever responding is then extinguished, and reinstatement of drug-
seeking behavior is subsequently triggered by a priming injec-
tion of a compound (drug-induced), a cue (or context) previ-
ously associated with the self-administration of the drug (cue-
or context-induced), or a stressor (stress-induced reinstatement)
(147). The reinstatement model of relapse to drug-seeking behav-
ior is uniquely responsive to drugs with addictive properties. Only
drugs which support drug-seeking and drug-taking behaviors
can initiate or trigger relapse in the reinstatement model. Espe-
cially, compelling is the fact that cross-priming (from one class of
addictive drug to another) is seen in this model (190).
Little work has been done with cannabinoids per se in this
model. However, existing literature in cannabinoid research indi-
cates that most of the reinstatement studies conducted with
cannabinoid compounds test for the cross-priming effect (i.e., the
interactions between cannabinoid compounds and other drugs of
abuse in inducing reinstatement of drug seeking) and is sugges-
tive of cannabinoids fitting the same pattern as other addictive
drugs in these procedures [for reviews, see Ref. (191–196)]. In
many cases, cannabinoids trigger reinstatement of drug-seeking
behavior in animals behaviorally extinguished from intravenous
drug self-administration behavior and, thus, pharmacologically
detoxified from their self-administered drug. Thus, in most cases,
either different drug of abuse has been used before extinction
(e.g., cocaine, heroin, morphine) or the drug-induced reinstate-
ment is triggered by cannabinoids or vice versa (186, 197) (please
see Table 4).
CB1 receptors have been found to play a critical role in
mediating reinstatement of previously extinguished drug-seeking
behavior upon re-exposure to the drug or drug-associated cues.
The neuroanatomical bases as well as the neuronal mechanisms
www.frontiersin.org July 2014 | Volume 5 | Article 92 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panagis et al. Cannabinoid regulation of brain reward
Table 4 | Cannabinoid effects on reinstatement of drug-seeking behavior in experimental animals.
Priming drug/cue/
stress factor
Dose Self-administration
drug
Dose Effect Species Reference
DRUG-INDUCED REINSTATEMENT
HU210 20 and 100µg/kg Cocaine 0.5 mg/kg
√
Male Wistar rats (198)
HU210 20µg/kg Heroin 50µg/kg/infusion
√
Male Wistar rats (199)
Heroin 0.25 mg/kg
√
SR1412716A+Heroin 3 mg/kg+0.25 mg/kg –
WIN 55,212-2 0.15 and 0.3 mg/kg Heroin 0.03 mg/kg/injection
√
Male Lister
Hooded rats
(200)
CP 55,940 0.05 and 0.1 mg/kg
√
∆9-THC 0.1–1.0 mg/kg No effect
SR1412716A+Heroin 0.3 mg/kg+0.1 mg/kg
Methamphetamine 1 mg/kg Methamphetamine 0.02 mg/kg/infusion
√
Male Wistar rats (201)
∆8-THC 0.32–3.2 mg/kg No effect
SR1412716A+∆8-
THC
3.2 mg/kg+1 mg/kg Decreased lever
press responses
WIN 55,212-2 0.25 and 0.5 mg/kg−1 WIN 55,212-2 12.5µg/kg/inf−1 √ Male Long Evans
rats
(202)
Heroin 0.5 mg/kg−1 √
Cocaine 10 mg/kg−1 –
SR 141716A mg/kg−1 No effect
SR+WIN/heroin 1 mg/kg−1 Blocks WIN/heroin-
reinstatement
Naloxone+WIN/heroin Blocks WIN/heroin-
reinstatement
∆9-THC 1 mg/kg Beer 4.5% ethanol v/v
√
Male Wistar rats (203)
Near-beer <0.5% ethanol v/v
√
Heroin 0.1 mg/kg Heroin 0.03 mg/kg/inf
√
Male Lister (204)
WIN 55,212-2 0.15 and 0.3 mg/kg
√
Hooded rats
CP55,940 0.05 and 0.1 mg/kg
√
SR141716A 0.3 mg/kg No effect
SR+WIN –
SR+CP –
SR+Heroin –
Methamphetamine 0.01–1.78 mg/kg Methamphetamine 0.1 mg/kg/infusion
√
Male Spreague-
Dawley rats
(205)
AM251+
Methamphetamine
0.032–0.32 mg/kg+
0.01–1.78 mg/kg
No effect on
methamphetamine
Methamphetamine mg/kg Methamphetamine 0.02 mg/
0.1 ml/infusion
√
Male Wistar rats (206)
HU210 10–32µg/kg per side
√
AM251+HU210 32µg/kg per side+
10–32µg/kg per side
–
URB597 0.3 mg/kg ∆9-THC 1 and 4µg/kg No effect Male Squirrel
monkeys
(189)
Anandamide 3 and 56µg/kg No effect
cocaine 1 and 30µg/kg No effect
∆9-THC 40µg/kg (end of
session)
∆9-THC 10, 20, 40 and
80µg/kg (total end
of session doses)
√
(except for the
lowest dose)
Male Squirrel
monkeys
(186)
SR141716A+∆9-THC 0.3 mg/kg (start)+40
µg/kg (end of session)
–
Natlrexone+∆9-THC 0.1 mg/kg (start)+40
µg/kg (end of session)
–
(Continued)
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Table 4 | Continued
Priming drug/cue/
stress factor
Dose Self-administration
drug
Dose Effect Species Reference
Nicotine 0.03 mg/kg/inf Nicotine 0.03 mg/kg/inf
√
Male Lister
Hooded rats
(207)
AM251+Nicotine 1, 3,
10 mg/kg+0.2 mg/kg
–
WIN55,212-2 0.15 or 0.3 mg/kg−1 WIN55,212-2 12.5 mg kg−1 per
infusion
Intact female rats
exhibited stronger
reinstatement than
males and
ovariectomized
females
Female Lister
Hooded rats
(208)
Female
ovariectomized
Lister Hooded
rats
Male Lister
Hooded rats
WIN55,212-2 0.15–0.3 mg kg(−1) Heroin 30µg kg−1/infusion √ Male Lister
Hooded rats
(209)
Naloxone 0.1–1 mg kg(−1) –
SR141716A 0.3–3 mg kg(−1) –
Selective adenosine
A(2A) receptor
antagonist MSX-3
1 and 3 mg/kg ∆9-THC 4µg/kg No effect Male Squirrel
monkeys
(210)
CUE-INDUCED REINSTATEMENT
House light and
click/light signal
3 mg/kg Heroin 50 µg/kg/infusion
√
Male Wistar rats (199)
SR1412716A –
WIN 55,212-2 0.3, 1, and 3 mg/kg
(daily during 5-day
extinction)
Cocaine 0.25 mg/kg/inf
√
(0.3 mg/kg) Male Wistar rats (211)
∆9-THC 5 mg/kg/day, perinatal Ethanol 3% v/v No effect Primiparous
Wistar female
rats
(212)
∆9-THC+ethanol 5 mg/kg/day+3% v/v No effect
SR-141716A 0.3–3.0 mg/kg –
AM404 0.4, 2 and 10 mg/kg Ethanol 10% v/v No effect Male Wistar rats (213)
AM251 32µg/kg per side Methamphetamine 0.02 mg/0.1 ml/infusion – Male Wistar rats (206)
Cue with or without
end of session
∆9-THC
40µg/kg (end of
session)
∆9-THC 10, 20, 40 and 80
µg/kg (total end of
session doses)
√
Male Squirrel
monkeys
(186)
SR141716A+Cue 0.3 mg/kg (start) –
Nicotine 0.03 mg/kg/inf Nicotine 0.03 mg/kg/inf
√
Male Lister
Hooded rats
(207)
AM251+Nicotine 1, 3,
10 mg/kg+0.2 mg/kg
–
Tone or Light Cue WIN55,212-2 12.5 mg kg−1 per
infusion
Intact female rats
exhibited stronger
reinstatement than
males and
ovariectomized
females
Female Lister
Hooded rats
(208)
Female
ovariectomized
Lister Hooded
rats
Male Lister
Hooded rats
STRESS-INDUCED REINSTATEMENT
(foot-shock) Ethanol 3% v/v Primiparous
Wistar female
rats
(212)
∆9-THC 5 mg/kg/day, perinatal No effect
∆9-THC+ethanol 5 mg/kg/day+3% v/v No effect
SR-141716A 0.3–3.0 mg/kg No effect
√
Induced reinstatement; – blocked reinstatement/blocked effects of CB1 agonists.
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of the relapse-promoting effects of CB1 receptor agonists or
the relapse-attenuating effects of CB1 receptor antagonists are
still poorly understood, although interactions of the endoge-
nous cannabinoid system with afferent glutamatergic and possibly
dopaminergic projections to the nucleus accumbens are most
likely involved (214).
Systemic injections of the potent CB1 receptor agonist HU-
210 dose-dependently reinstate cocaine-seeking behavior in labo-
ratory rats behaviorally extinguished from intravenous cocaine
self-administration (198). Systemic injections of HU-210 also
reinstate heroin-seeking behavior in laboratory rats behaviorally
extinguished from intravenous heroin self-administration (199).
Interestingly, however, the same research group found that the
CB1 cannabinoid receptor antagonist SR-141716A blocked rein-
statement to drug-seeking behavior triggered by cocaine, heroin,
or cocaine-associated environmental cues, but not reinstatement
induced by exposure to stress, suggesting a potential role for
cannabinoid antagonists in the treatment of addiction. Cue-
induced reinstatement to cocaine seeking has also been found
when rats were administered with different doses of WIN55,212-
2 (0.3, 1, and 3 mg/kg) during a 5-day extinction period. In
this case, the lowest dose of WIN55,212-2 (0.3 mg/kg) induced
the highest resistance to extinction and reinstatement (i.e.,
the highest responding at the active lever during conditioned-
reinstatement) (211).
Interestingly, however, squirrel monkeys did not self-
administer the FAAH inhibitor URB597, and the drug did not pro-
mote reinstatement of extinguished drug-seeking behavior previ-
ously maintained by∆9-THC, anandamide, or cocaine (189). Fur-
ther, reinstatement to∆9-THC-seeking behavior does not seem to
be affected by striatal adenosine receptors, as the selective adeno-
sine A(2A) receptor antagonist MSX-3 (1 mg/kg) neither pro-
moted reinstatement of extinguished drug-seeking behavior nor
altered reinstatement of drug-seeking behavior by non-contingent
priming injections of ∆9-THC (210).
In another study using psychostimulants (201), following
12 days of self-administration of methamphetamine (METH),
under extinction conditions, METH-priming or re-exposure to
cues previously paired with METH infusion triggered reinstate-
ment of METH seeking. The cannabinoid CB1 receptor antag-
onist SR141716A blocked this effect, while administration of
the cannabinoid agonist, ∆8-tetrahydrocannabinol (∆8-THC),
had no effect by itself, and co-administration of the ∆8-THC
and METH at small doses reinstated the drug-seeking behavior.
Interestingly,∆8-THC attenuated the effects of the reinstatement-
inducing dose of METH, but enhanced the effect of cues. Either
given repeatedly during the extinction or singly, 24 h before the
first METH-priming or cues challenge, ∆8-THC suppressed the
reinstatement (201). These results suggest that the endocannabi-
noid system may be involved in the reinstating effects of METH-
priming and cues. A follow-up study by the same group exam-
ined whether the reinstatement involves interactions between CB1
and nicotinic acetylcholine receptors (nAChRs) in the reinstate-
ment of METH-seeking behavior (206). Systemic and intracra-
nial administration of the potent CB1 receptor agonist HU210
into the nucleus accumbens core and prelimbic cortex rein-
stated METH-seeking behavior. The reinstatement caused by the
systemic HU210 treatment was attenuated by intracranial admin-
istration of the CB1 receptor antagonist AM251 into the regions
mentioned above, while reinstatement induced by the METH-
associated cues and METH-priming injection was also attenuated
by intracranial administration of AM251 in each region. Inter-
estingly, in these regions, the attenuating effects of AM251 on
the reinstatement induced by each stimulus were blocked by
the intracranial administration of mecamylamine, a non-selective
nAChR antagonist, but not by scopolamine, a muscarinic ACh
receptor (mAChR) antagonist. Moreover, the intracranial admin-
istration of DHβE, anα4β2 nAChR antagonist, but not MLA, anα7
nAChR antagonist, into each region blocked the AM251-induced
attenuation of the reinstatement. These findings suggest that rein-
statement (or relapse in humans) to MAP-seeking behavior may be
due to two steps: inhibition of ACh transmission by the activation
of cannabinoid CB1 receptors and inactivation of α4β2 nAChRs
(206). On the contrary, another study using AM251 did not modify
METH-induced reinstatement of METH-seeking behavior (205).
The effects of the selective CB1 receptor antagonist AM251
have also been tested in nicotine-seeking behavior (207), where it
has been found to dose-dependently (1–10 mg/kg) attenuate the
reinstatement effects produced by both a nicotine priming dose
(0.2 mg/kg) and its contingently presented cues.
Similarly to the studies presented above, Fattore and colleagues
(200) showed that intraperitoneal priming injections of the potent
non-selective CB1/CB2 receptor agonists WIN 55,212-2 (0.15 and
0.3 mg/kg) and CP 55,940 (0.05 and 0.1 mg/kg), but not ∆9-THC
(0.1–1.0 mg/kg), effectively restored heroin-seeking behavior. In
the same study, intraperitoneal priming injection of the CB1 recep-
tor antagonist SR141716A (0.3 mg/kg) did not reinstate respond-
ing, but completely prevented heroin-induced reinstatement of
drug-seeking behavior. Moreover, heroin-seeking behavior was
still present for a few days following cannabinoid primings, indi-
cating a long-lasting effect of cannabinoids on responding for
heroin. These findings indicate that relapse to heroin after an
extended drug-free period is triggered by cannabinoid agonists
and that SR 141716A prevents drug-seeking behavior, suggesting
that the use of the cannabinoid antagonists could have some thera-
peutic benefits in heroin-induced relapse (200). A follow-up study
also presented similar findings (204). In continuation of the above
study, a very interesting study from the same group showed that
rats previously trained to intravenously self-administer the CB1
receptor agonist WIN 55,212-2 (12.5µg/kg/inf) showed reinstate-
ment in WIN 55,212-2-seeking behavior after priming injections
of either the previously self-administered CB1 agonist (0.25 and
0.5 mg/kg) or heroin (0.5 mg/kg), but not cocaine (10 mg/kg), fol-
lowing 3 weeks of extinction. The selective CB1 receptor antagonist
SR 141716A (0.3 mg/kg) did not reinstate responding when given
alone, but completely prevented the cannabinoid-seeking behav-
ior triggered by WIN 55,212-2 or heroin primings. Further, the
non-selective opioid antagonist naloxone (1 mg/kg) had no effect
on operant behavior per se, but significantly blocked cannabinoid-
and heroin-induced reinstatement of cannabinoid-seeking behav-
ior (202).
Most recently, WIN55,212-2-induced reinstatement of heroin-
seeking behavior was significantly attenuated by naloxone
(1 mg/kg) and rimonabant (3 mg/kg) and fully blocked by
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co-administration of sub-threshold doses of the two CB1 receptor
antagonists. Moreover, contrary to immediate (1 day) or delayed
(90 days) drug substitution, rats readily self-administered WIN
when access was given after 7, 14, or 21 days of extinction from
heroin, and showed a response rate that was positively correlated
with the extinction period (209). Taken together, this set of data
suggests some strong interactions between the cannabinoid and
opioid systems in relapse mechanisms.
In relation to ethanol/alcohol-seeking behavior, ∆9-THC
(1 mg/kg) significantly reinstated responding, previously rein-
forced with beer or near-beer (low alcohol beer) (203), while
the anandamide transport inhibitor AM404 did not affect cue-
induced reinstatement of alcohol-seeking behavior (213). On the
other hand, perinatal administration of ∆9-THC (5 mg/kg, daily)
either alone or in combination with ethanol (3% v/v) did not affect
alcohol self-administration or alcohol seeking in any of the rat
groups, while SR141716A (0.3–3.0 mg/kg) significantly reduced
lever pressing for ethanol and blocked conditioned reinstate-
ment of alcohol seeking, although the same doses of SR141716A
failed to block foot-shock stress-induced reinstatement of alcohol
seeking (212).
Finally, sex differences and ovarian hormones also appear to
play a role in modulating cannabinoid-seeking behavior after
exposure to drug priming or drug-asociated cues. In the study
by Fattore and colleagues (208), after a priming dose of 0.15 or
0.3 mg/kg WIN55,212-2, intact female rats exhibited stronger rein-
statement than males and ovariectomized females. Responses of
intact female rats were higher than those of male and ovariec-
tomized rats even after priming with a drug-associated visual or
auditory cue, or a WIN55,212-2+Cue combination (208).
In summary, the majority of the studies presented show that
CB1 receptor agonists or endocannabinoid enhancers tend to pro-
mote either drug-, or cue-, or stress-induced reinstatement of
drug-seeking behavior either to cannabinoid compounds or to
other drugs of abuse. Overall, the above findings indicate that
the endocannabinoid system, and in particular the CB1 receptors,
play an important role in the processes underlying reinstatement
to different drugs of abuse, such as psychostimulants (e.g., cocaine,
methamphetamine, and nicotine), opioids (e.g., heroin) and alco-
hol. Further research will help clarify the mechanisms underlying
these drug interactions and cross-priming effects in reinstatement
processes.
CONCLUSION
Although the euphorigenic properties of cannabis preparations
have been appreciated by humans for centuries, only the last
years we have acquired the experimental tools to evaluate cannabi-
noid reward and abuse liability in experimental animals. It is now
clear that cannabinoids exert emotional and motivational effects
in experimental animals and can activate the same reward cir-
cuits in the brain and produce drug reinforcement/drug-seeking
behavior, although under more limited conditions. The reward-
ing properties of ∆9-THC are clearly shown by a decrease
in brain-stimulation reward thresholds and self-administration
behavior. However, CB1 receptor agonists and endocannabinoid
modulators (indirect agonists) do not affect the reinforcing effi-
cacy of brain stimulation and are self-administered basically
under particular experimental conditions. Moreover, contrasting
findings have been shown in the CPP paradigm, where cannabi-
noids produce both positive (rewarding) and negative (aversive)
effects, depending on the specific experimental procedures fol-
lowed. Beyond any doubt, cannabinoids and the endocannabinoid
system appear to be involved in reinstatement of extinguished
self-administration of several drugs of abuse. Much remains to be
done before we fully understand the actions of cannabinoids in
critical areas of the reward circuit that mediate both rewarding
and aversive phenomena and relapse mechanisms. Furthermore,
since new cannabinoid-related medications are being developed,
there will be a need to assess their potential rewarding actions
and abuse liability, using the animal models and experimental
procedures described here. The fact, for example, that enhance-
ment of endocannabinoid neurotransmission does not increase
brain reward, neither produces reward-related behaviors makes
the drugs that directly affect endocannabinoid levels promis-
ing therapeutics, with less unwanted side-effects and minimal
abuse potential.
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